Expression of heregulin by mouse mammary tumor cells: Role in activation of ErbB receptors

Molecular Carcinogenesis

Volumn 45, Issue 7, 2006, Pages 490-505

  Schmitt, M ^a   Walker, M P ^a   Richards, R G ^a   Bocchinfuso, W P ^a   Fukuda, T ^a   Medina, D ^b   Kittrell, F S ^b   Korach, K S ^a   DiAugustine, R P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Poliferation; Poteolytic cleavage; Tyrosine phosphorylation

Indexed keywords

ANTISERUM; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LIGAND; NEU DIFFERENTIATION FACTOR; OLIGONUCLEOTIDE; PROTEIN PRECURSOR; PROTEIN TYROSINE KINASE; RECEPTOR PROTEIN; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TUMOR EXTRACT; TYROSINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; LIGAND BINDING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE NEU; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; RECEPTOR BINDING; RETROVIRUS INFECTION; TUMOR CELL CULTURE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEUREGULIN-1; PEPTIDE FRAGMENTS; PLASMIDS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 33745714328     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20180     Document Type: Article

References (59)

1. Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 1995;6:135-145.
2. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994;91: 8132-8136.
3. Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-48.
4. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling. J Mam Gland Biol Neoplasia 1997;2:97-107.
5. Chen X, Levkowitz G, Tzahar E, et al. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 1996;271:7620-7629.
6. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Embo J 1995;14:4267-4275.
7. Sliwkowski MX, Schaefer G, Akita RW, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269:14661-14665.
8. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003;100:8933-8938.
9. Sebastian J, Richards RG, Walker MP, et al. Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ 1998;9:777-785.
10. Carraway KL 3rd, Burden SJ. Neuregulins and their receptors. Curr Opin Neurobiol 1995;5:606-612.
11. Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14:3550-3558.
12. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-184.
13. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. Embo J 1999; 18:2149-2164.
14. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758-765.
15. Bodey B, Bodey B, Jr., Groger AM, et al. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 1997; 17:1319-1330.
16. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86:9193-9197.
17. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10: 1813-1821.
18. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89: 10578-10582.
19. Zhou H, Liu L, Lee K, et al. Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea. Oncogene 2002;21:8732-8740.
20. Bacus SS, Gudkov AV, Zelnick CR, et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: Implications for mammary tumors. Cancer Res 1993;53:5251-5261.
21. Guerra-Vladusic FK, Scott G, Weaver V, et al. Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. Int J Oncol 1999;15:883-892.
22. Le XF, Vadlamudi R, McWatters A, et al. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 2000;60:3522-3531.
23. Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 1997;57:3804-3811.
24. Normanno N, Ciardiello F, Brandt R, Salomon DS. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat 1994;29: 11-27.
25. Aguilar Z, Akita RW, Finn RS, et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 1999;18:6050-6062.
26. Meiners S, Brinkmann V, Naundorf H, Birchmeier W. Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene 1998;16:9-20.
27. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003;1:165-175.
28. Krane IM, Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996;12:1781-1788.
29. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988;55:619-625.
30. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54: 105-115.
31. Reilly RT, Gottlieb MB, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-3576.
32. Kittrell FS, Oborn CJ, Medina D. Development of mammary preneoplasias in vivo from mouse mammary epithelial cell lines in vitro. Cancer Res 1992;52:1924-1932.
33. Danielson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc Natl Acad Sci USA 1984;81:3756-3760.
34. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992; 256:1205-1210.
35. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophageT4. Nature 1970;227: 680-685.
36. Balana ME, Lupu R, Labriola L, Charreau EH, Elizalde PV. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene 1999;18:6370-6379.
37. Wen D, Peles E, Cupples R, et al. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992;69:559-572.
38. Friedman J, Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA. Cell 1991;66:799-806.
39. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory Press; 1989. pp 1.82-1.84.
40. Bortner CD, Cidlowski JA. Caspase independent/dependent regulation of K(+), cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis. J Biol Chem 1999;274:21953-21962.
41. Wen D, Suggs SV, Karunagaran D, et al. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol 1994;14:1909-1919.
42. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287.
43. Normanno N, Kim N, Wen D, et al. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat 1995;35:293-297.
44. Yang Y, Spitzer E, Meyer D, et al. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol 1995;131:215-226.
45. Ethier SP, Langton BC, Dilts CA. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha. Mol Carcinog 1996;15:134-143.
46. Burgess TL, Ross SL, Qian YX, Brankow D, Hu S. Biosynthetic processing of neu differentiation factor. Glycosylation trafficking, and regulated cleavage from the cell surface. J Biol Chem 1995;270:19188-19196.
47. Harris A, Adler M, Brink J, et al. Homologue scanning mutagenesis of heregulin reveals receptor specific binding epitopes. Biochem Biophys Res Commun 1998;251:220-224.
48. Weinstein EJ, Leder P. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis. Cancer Res 2000;60: 3856-3861.
49. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;256:1093-1095.
50. Nielsen UB, Cardone MH, Siskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. PNAS 2003;2003:9330-9335.
51. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation. PNAS 1994;91:1500-1504.
52. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000;2:203-210.
53. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestorgen receptor in human breast cell lines. Int J Cancer 2000; 87:487-498.
54. Mincione G, Bianco C, Kannan S, et al. Enhanced expression of heregulin in c-erb B-2 and c-Ha-ras transformed mouse and human mammary epithelial cells. J Cell Biochem 1996; 60:437-446.
55. Lupu R, Cardillo M, Cho C, et al. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 1996;38:57-66.
56. Li Q, Ahmed SL, Loeb JA. Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells. Cancer Res 2004;64:7078-7085.
57. Hijazi MM, Thompson EW, Tang C, et al. Heregulin regulates the actin cytosceleton and promotes invasive propoerties in breast cancer cell lines. Int J Oncol 2000;17:629-641.
58. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003;22:761-768.
59. Ram TG, Schelling ME, Hosick HL. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification. Cell Growth Differ 2000;11:173-183.